works in Detail
EVOCellic enables fast and effective healing by stimulating the skin’s natural healing process. EVOCellic is based on keratinocytes being the ‘active component’, which contain and release growth factors. The release of growth factors into the wound bed allows the remaining cells to proliferate and close the wound, while also signaling for migration of more keratinocytes and fibroblast to the wound site.
The product will follow the regulatory path for Advanced Therapy Medicinal Product (ATMP) marketing authorization in Europe.
EVOCellic is in the preclinical stage of development, with clinical proof of concept data expected in 2028.